Análisis Argos
KNSA
KNSACara
Kiniksa Pharmaceuticals International, plc · Healthcare
US$ 64.53
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
54/100
LA RESPUESTA
El mercado le pide crezca 60% al año — más de lo que ha demostrado (14.4%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO6/6PASADO4/6SALUD5/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO6/6PASADO4/6SALUD5/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoEl dividendo aún duerme
Score Argos54de 100Cara
Ingresos▲62%
US$ 0.7 B
Margen operativo▼206%
11.4%
Flujo de caja libre▲0%
US$ 0 B
Deuda neta
US$ -0.2 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.9B
P/E82.2x
EV/EBITDA59.6x
FCF yield0.5%
ROIC12.5%
Margen operativo11.4%
Crecim. ingresos+60.1%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 30 jun
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com · 30 jun
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com · 29 jun
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
zacks.com · 26 jun
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
gurufocus.com · 22 jun
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says Overvalued
On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing the current price to $57.13. The stock has shown strong perf
zacks.com · 19 jun
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zacks.com · 18 jun
New Strong Buy Stocks for June 18th
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
zacks.com · 16 jun
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.